CASSAVA SCIENCES INC (SAVA) Stock News

USA - Nasdaq - NASDAQ:SAVA - US14817C1071 - Common Stock

3.25 USD

-0.14 (-4.13%)

Last: 11/28/2025, 8:00:03 PM

3.25 USD

0 (0%)

After Hours: 11/28/2025, 8:00:03 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SAVA Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Chartmill - Mentions: ICON KEYS JAGX PLAG ...

News Image

Get insights into the top gainers and losers of Monday's after-hours session.

19 days ago - By: Cassava Sciences, Inc.

Cassava Reports Q3 2025 Financials Results and Provides Business Update

19 days ago - By: Cassava Sciences, Inc.

Cassava Reports Q3 2025 Financials Results and Provides Business Update

a month ago - By: Halper Sadeh LLC

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

a month ago - By: Cassava Sciences, Inc.

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

a month ago - By: Cassava Sciences, Inc.

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

2 months ago - By: Benzinga - Mentions: PBM SNGX KPTI SSKN ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

2 months ago - By: Benzinga

Cassava Sciences (SAVA) Stock Is Surging Tuesday: What's Going On?

3 months ago - By: Cassava Sciences, Inc.

Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Cassava Sciences, Inc.

Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: The Motley Fool

Cassava Sciences Posts Q2 Loss on Pivot

4 months ago - By: Cassava Sciences, Inc.

Cassava Reports Q2 2025 Financials Results and Provides Business Update

4 months ago - By: Cassava Sciences, Inc.

Cassava Reports Q2 2025 Financials Results and Provides Business Update

4 months ago - By: Cassava Sciences, Inc.

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

4 months ago - By: Cassava Sciences, Inc.

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

4 months ago - By: Cassava Sciences, Inc.

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

4 months ago - By: Cassava Sciences, Inc.

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

5 months ago - By: Cassava Sciences, Inc.

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

5 months ago - By: Cassava Sciences, Inc.

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

7 months ago - By: Cassava Sciences, Inc.

Cassava Reports Q1 2025 Financials Results, Provides Business Update

7 months ago - By: Cassava Sciences, Inc.

Cassava Reports Q1 2025 Financials Results, Provides Business Update

7 months ago - By: Cassava Sciences, Inc.

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

7 months ago - By: Cassava Sciences, Inc.

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

7 months ago - By: Cassava Sciences, Inc.

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

7 months ago - By: Cassava Sciences, Inc.

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development